ESMO 2025 | Incorporating neoadjuvant immunotherapies in rare skin cancers
Janice Mehnert, MD, Perlmutter Cancer Center of NYU Langone Health, New York, NY, comments on the potential applications of immunotherapy and radiation in treating squamous carcinoma and other diseases like basal cell carcinoma. Clinicians will need to weigh the benefits of immunotherapy against the risk of toxicities and also consider the future use of neoadjuvant therapy in rare and aggressive skin malignancies, such as Merkel cell carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that’s a really important question to understand how we can use these findings to look at future results. I think for instance we’re learning a lot about how to incorporate immunotherapy and radiation for squamous carcinoma as well and perhaps we’ll think about it for other diseases like basal cell carcinoma for instance. I think in, what we need to understand is how does giving the immunotherapy, does the benefit justify the risk of toxicities? So that’s an important question to think about...
I think that’s a really important question to understand how we can use these findings to look at future results. I think for instance we’re learning a lot about how to incorporate immunotherapy and radiation for squamous carcinoma as well and perhaps we’ll think about it for other diseases like basal cell carcinoma for instance. I think in, what we need to understand is how does giving the immunotherapy, does the benefit justify the risk of toxicities? So that’s an important question to think about. I also think it’s important for us to think about the future with neoadjuvant therapy and Merkel and other rare and aggressive skin malignancies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
